Camlipixant is an orally administered antagonist of the ATP-sensing P2X3 homotrimeric receptor ion channel, originated by AstraZeneca AB and assigned to the Canadian NEOMED Institute (now adMare), and developed by BELLUS Health (Canada), for the treatment of chronic cough. Chronic cough remains difficult to treat – the last FDA-approved anti-tussive, dextromethorphan, was first approved in 1958 and has demonstrated limited clinical efficacy. [...]
8 minute read
Jun. 18, 2023
A P2X3-Selective Antagonist for Chronic Cough Without Taste Effects
camlipixant
oral BID P2X3 receptor antagonist Ph. III for first-line treatment of refractory chronic cough non-competitive homotrimeric receptor antagonist; discovery not disclosed GSK acquisition announcement, April 18, 2023 AstraZeneca Canada/NeoMed (adMare)/Bellus Health/GSK
Loading...
